Renalytix Share Discussion Threads

[homebrewruss] 23/8/2020 20:10

Currency fluctuations don't affect spreadbets when you are buying/selling as you are just paying pound(s) per point.

[faz] 23/8/2020 20:05

Currency fluctuations

[homebrewruss] 23/8/2020 20:02

Has anyone got any preference between buying US Vs UK stock. Assuming prices are roughly the same and assuming no exchange costs?
I'm thinking of buying a bit more stock on a spread bet and wondering of any drawbacks I may not have thought of for buying some US listed stock?

[74tom] 22/8/2020 10:27

Interesting video posted yesterday by a US Twitter account with around 7k followers:



They highlight the RNLX IPO in light of the AZN news, and state they are going to release a full research piece this weekend. Will keep an eye out for it.

The host has never heard of RNLX & his initial questions relate to the size of the total addressable market, industry macro trends etc etc. Pretty sure they’ll be investing once they do a little bit of research.

Also always worth bearing in mind that it would take only 5000 US investors owning an average of 2k ordinary shares / 1k ADS each to fill 10m of free float.

Yesterday’s news definitely helped to get the story out, and should pique some serious interest. Let’s hope we continue to sign collaborations with Top 10 Global Pharmas - Johnson & Johnson / Merck / Pfizer would be a great next step...

[2theduke] 21/8/2020 19:47

It must be overhang from either jpmorgan or from someone in the initial placing... the rns today gave someone volume to sell shares, volume they can only get on a rns day.
I’m guessing the jpm $19 broker report, which was the catalyst for the very start of the us downtrend last week after the quiet period is playing its part.
It is a positive rns without a doubt, eventually value will play through no doubt you’d think

[74tom] 21/8/2020 18:56

6% down on that news is just ridiculous.

I’m guessing that in an ideal world they would have preferred to wait until they had their first revenues confirmed in the statutory accounts before listing to avoid such ludicrous swings, but there’s no way they could have raised $85m on AIM!

[nimbo1] 21/8/2020 18:26

That’s my point. Price can do anything until revenues come through...but hopefully continue up after this weird down move on Nasdaq. It’s incredibly bizarre in the face of good news!

[charlieej] 21/8/2020 18:12

In a pre revenue business most news will be lacking in detail on the financials. Being legitimised by Astra Zeneca would ordinarily be viewed very positively. I can only assume someone stateside has been awaiting a volume enhancing event to exit for reasons unrelated to RENX.

[nimbo1] 21/8/2020 17:46

Nuts move! Bought some on Nasdaq just now! Weird going’s on After such a nice rns. Guess it’s a jam tomorrow rns...

[74tom] 21/8/2020 16:51

It almost feels like an institution has taken a short position, potentially to control the share price or at least prevent it from taking off. A 70k trade is almost exactly $1m, so certainly not a retail investor. I don't see any reason that an existing holder would sell $1m at 17% below the current price, unless they were very desperate!

Nevermind, the weighing machine analogy of Ben Graham will win out if RENX keeps delivering news like today's. And I agree with you @Wan, I think the scale of the partnership will become apparent over the next year. Also great news that we'll be getting reimbursed our R&D spend + a margin on top :)

[charlieej] 21/8/2020 16:31

Anyone have any potential reason for that spike down?

[74tom] 21/8/2020 16:11

Yes I just saw that ridiculous spike down - my guess would be JP Morgan have decided to dump their IPO shares. Very frustrating to now be down on the day over there after such good news.

[peterc1970] 21/8/2020 16:09

No volume on Nasdaq, and then 70k or so sold which spiked it down to $14 in one go. Back to flat on the day there

[wan] 21/8/2020 16:07

The collaboration with Astrazeneca is indeed notable for a number of reasons. Fwiw, I am of the opinion there is more to come in terms of such collaborations. With the reference to diabetes and cardiovascular disease perhaps providing another clue? Time will tell.

[faz] 21/8/2020 14:57

I think thats the point here Wan. The wider the customer base the better for RENX and there's not many with a bigger profile than Astrazeneca.

[wan] 21/8/2020 14:27

Today's news provides much food for thought.

Not only will the collaboration identify and realise improved patient outcomes, it will look to optimise both exiting and novel therapeutics and accelerate patient identification and recruitment for clinical trials.

Optimising drug development/utilisation and the progressive enrichment of clinical trial populations utilising KidenyIntelX, in my view, is likely to pique other therapeutic/pharma interest.

[nimbo1] 21/8/2020 10:43

Broker comment on research tree interesting. Don't have time to write it out but renx will earn a margin on top their costs / time etc which is good news.

If renx solution becomes part of the drug testing process to understand impacts on patient populations, potential is way larger than even I first thought when analysing this from an optimistic perspective!

[mr roper] 21/8/2020 08:43

Yes, pretty exciting news. Looking like a busy H1 for readouts.

[74tom] 21/8/2020 08:24

Yep, I did think it had been very quiet! The interesting part from first read is; "to develop and launch precision medicine strategies for cardiovascular, renal and metabolic diseases."

So confirmation of future development beyond renal disease into other significant disease areas.

I suspect NASDAQ will like this announcement...

[mr roper] 21/8/2020 08:04

Wow..late rns this morning. Partnership with AstraZeneca looks very promising

[wan] 20/8/2020 06:50

I would add that Kantaro's patient test would perhaps also be very useful post antibody drug treatment -